Dr. 丹尼斯Slamon, a world-renowned oncologist and scientist whose groundbreaking research has transformed the treatment of breast cancer, has been awarded the 2024 Szent-Györgyi Prize for Progress in 癌症 研究 from the National Foundation for 癌症 研究.
The prize has been awarded annually since 2006 to honor an outstanding scientist whose body of work has had a lasting impact on the understanding of cancer, significantly improving or saving the lives of people with the disease.
The foundation recognized Slamon for his seminal contributions to cancer research that helped shape the field of precision medicine in breast cancer and paved the way for the development of other targeted therapies in oncology.
"I am honored and humbled to receive this prestigious award,”斯拉蒙说。, 临床和转化研究主任 皇冠hga025大学洛杉矶分校健康约翰逊综合癌症中心 也是血液学和肿瘤学主任 皇冠hga025大学洛杉矶分校大卫·格芬医学院. “这种认可不只是给我的, 但对于无数的研究人员来说, 临床医生, and especially the brave women who have participated in our clinical trials. 在一起, we have changed the landscape of breast cancer treatment and continue to work on developing cancer treatments that can move from the bench to the bedside more rapidly."
Slamon首先发现了HER2基因, which is overexpressed in about 25-30% of breast cancer cases and is associated with a more aggressive form of the disease. This non-inherited genetic change defined a new subtype of breast cancer.
This research and subsequent clinical trials led by Slamon resulted in the development of the breast cancer drug Herceptin, 这是美国批准的首个基因药物.S. 来对抗癌症. 自1998年推出以来, Herceptin has become a cornerstone in the treatment of HER2-positive breast cancer, 惠及全球数百万妇女.
“Dr. Slamon created a new paradigm for modern translational cancer research,” said Dr. 迈克尔Teitell, director of the 皇冠hga025大学洛杉矶分校健康约翰逊综合癌症中心. “His discoveries emphasized the importance of targeting the molecular mechanism, 不是癌症的组织学, 哪些已经成为大多数新的癌症治疗的基础. 他激励了医生和研究者, 包括我自己, to look beyond their existing assumptions to find more effective ways to treat people with cancer.”
除了赫赛汀, Slamon and his team also spearhead the development of the initial targeted inhibitor of CDK-4/6, palbociclib (Ibrance), which was approved by the FDA for women with advanced estrogen receptor-positive, her -2阴性乳腺癌, 这种疾病最常见的亚型. Palbociclib靶向CDK-4/6, a critical enzyme that is involved in regulating cell division, 防止细胞分裂. The use of palbociclib and others drugs in its class has doubled the number of women with the disease who live without any recurrence of the cancer – the largest improvement since the introduction of hormone therapy for breast cancer in the early 1970s.
“I can think of none finer to receive the 2024 Szent Györgyi Prize than Dr. 砰!. Isaac Witz Chair of the 2024 Selection Committee and 2023 Szent-Györgyi Prize Winner in the National Foundation for 癌症 研究’s announcement. “The scientific and medical advances he has made for women with breast cancer have created a new paradigm for treatment options and resulting survival rates. 我知道有一位医生. Slamon’s research for some time and have sincerely admired his approaches, 他和这个领域的其他人有什么不同, and his tenacity to tackle the clinical trial process head on to produce results for patients.”
"Dr. Slamon体现了我们对一个 Szent-Györgyi获奖者. One of my favorite quotes from our co-founder Albert Szent-Györgyi is ‘to see what others have seen but to think differently than anybody else has thought.’ Dr. Slamon has done just this through his research around the amplification of the HER2 gene, which shed even more light on cancer being a genetic disease and paved the way for a completely new set of targeted treatments for breast cancer patients. Over time as his research produced more and more positive results for cancer patients, many of his research and medical peers began to adopt the viewpoint of ‘breast cancer before Dennis and after Dennis.’ We 我非常荣幸地邀请到. Slamon是我们2024年Szent-Györgyi奖得主. Sujuan英航, NFCR's President and CEO and the Co-Chair of the 2024 Szent-Györgyi Prize Selection Committee.
Szent-Györgyi癌症研究进展奖, 以艾伯特命名Szent-Györgyi, Nobel laureate and co-founder of National Foundation for 癌症 研究, will be presented to Slamon at The National Press Club in Washington, 10月DC. 在…期间 Szent-Györgyi Prize Dinner and Award Ceremony, the foundation's signature event of its daylong 全球癌症研究峰会和颁奖典礼 & 创业. The award highlights the foundation’s investment in funding long-term and transformative pioneering research that will produce scientific breakthroughs and promote public awareness of the importance of basic cancer research.
